<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00863798</url>
  </required_header>
  <id_info>
    <org_study_id>3151A1-3362</org_study_id>
    <secondary_id>B2061005</secondary_id>
    <secondary_id>3151A1-3362-US</secondary_id>
    <nct_id>NCT00863798</nct_id>
  </id_info>
  <brief_title>Study Evaluating Desvenlafaxine Succinate Sustained Release In Adults With Major Depressive Disorder</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Evaluate The Efficacy And Safety Of 2 Fixed Doses (10 And 50 mg/Day) Of DVS SR Tablets In Adult Outpatients With Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to compare the antidepressant efficacy and safety of two
      doses of desvenlafaxine succinate sustained release (10 and 50 mg/day) in adults with Major
      Depressive Disorder. The study will also assess changes in sexual function and general and
      functional quality of life outcomes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in HAM-D17 Total Score at Final On-therapy (FOT) Evaluation (Week 8 or ET)</measure>
    <time_frame>Baseline and Week 8 (or ET)</time_frame>
    <description>HAM-D17: a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Items are scored on either a 3 point (0 to 2) or a 5 point scale (0 to 4), with 0=none/absent and 4=most severe, for a maximum total score of 50.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Categorical Scores on CGI-Improvement (CGI-I) at FOT Evaluation (Week 8 or ET)</measure>
    <time_frame>Week 8 (or ET)</time_frame>
    <description>CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean CGI-S Score at FOT Evaluation (Week 8 or ET)</measure>
    <time_frame>Baseline and Week 8 (or ET )</time_frame>
    <description>CGI-S: 7-point clinician rated scale to assess severity of participant's current illness state; range: 1 (normal - not ill at all) to 7 (among the most extremely ill patients). Higher score = more affected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in MADRS Total Score at FOT Evaluation (Week 8 or ET)</measure>
    <time_frame>Baseline and Week 8 (or ET)</time_frame>
    <description>MADRS measures the overall severity of depressive symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HAM-D6 Total Score at FOT Evaluation (Week 8 or ET)</measure>
    <time_frame>Baseline and Week 8 (or ET )</time_frame>
    <description>HAM-D6: a standardized, clinician-administered rating scale that assesses 6 items characteristically associated with major depression and is a subset of HAM-D17. HAM-D6 score ranges from 0-22. 0=none/absent and 22=most severe.The scale uses HAM-D17 items: 1, 2, 7, 8, 10 and 13. Item 13 is scored 0-2 and all others are scored 0-4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Response on the HAM-D17 at FOT Evaluation (Week 8 or ET)</measure>
    <time_frame>Week 8 (or ET)</time_frame>
    <description>A HAM-D17 responder was defined as a participant with a 50% or greater decrease from baseline in HAM-D17 score. HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Individual items are scored on either a 3 point (0 to 2) or a 5 point scale (0 to 4), with 0=none/absent and 4=most severe, for a maximum total score of 50.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants in Remission Based on the HAM-D17 at FOT Evaluation (Week 8 or ET)</measure>
    <time_frame>Week 8 (or ET)</time_frame>
    <description>Remission was defined as a HAM-D17 score of less than or equal to 7. HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Individual items are scored on either a 3 point (0 to 2) or a 5 point scale (0 to 4), with 0=none/absent and 4=most severe, for a maximum total score of 50.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Response on the MADRS Score at FOT Evaluation (Week 8 or ET)</measure>
    <time_frame>Week 8 (or ET)</time_frame>
    <description>A MADRS responder was defined as a participant with a 50% or greater decrease from baseline in MADRS score. It measures the overall severity of depressive symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Response on the CGI-I Score at FOT Evaluation (Week 8 or ET)</measure>
    <time_frame>Week 8 (or ET)</time_frame>
    <description>CGI-I responder was defined as a participant with a score of 1 (very much improved) or 2 (much improved) on the CGI-I. CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">682</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Desvenlafaxine succinate sustained release 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Desvenlafaxine succinate sustained release 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desvenlafaxine Succinate Sustained-Release 10mg</intervention_name>
    <description>10 mg tablet, once daily dosing for 8 weeks</description>
    <arm_group_label>Desvenlafaxine succinate sustained release 10 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desvenlafaxine Succinate Sustained-Release 50 mg</intervention_name>
    <description>50 mg tablet, once daily dosing for 8 weeks</description>
    <arm_group_label>Desvenlafaxine succinate sustained release 50 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Matching placebo tablets (10 or 50mg). Daily dosing for 10 +/- 4 days during a placebo lead-in period, and then 8 weeks during the double-blind period.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult, outpatient with primary diagnosis of Major Depressive Disorder (depressive
             symptoms for at least 30 days prior to screening).

          -  Hamilton Psychiatric Rating Scale for Depression (HAM-D 17) total score of &gt;= 20.

          -  Clinical Global Impressions Scale-Severity (CGI-S) score of &gt;= 4.

        Exclusion Criteria:

          -  Clinical instability (25% or greater increase/decrease in HAM-D 17 total score from
             screening to baseline).

          -  Significant risk of suicide as assessed by clinician judgment, HAM-D 17 and Columbia
             Suicide-Severity Rating Scale scores Other eligibility criteria also apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Redlands</city>
        <state>California</state>
        <zip>92374</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cromwell</city>
        <state>Connecticut</state>
        <zip>06416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>North Miami</city>
        <state>Florida</state>
        <zip>33161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63139</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10312</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Salem</city>
        <state>Oregon</state>
        <zip>97301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Media</city>
        <state>Pennsylvania</state>
        <zip>19063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Herndon</city>
        <state>Virginia</state>
        <zip>20170</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Midlothian</city>
        <state>Virginia</state>
        <zip>23112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Middleton</city>
        <state>Wisconsin</state>
        <zip>53562</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Waukesha</city>
        <state>Wisconsin</state>
        <zip>53188</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=3151A1-3362&amp;StudyName=Study%20Evaluating%20Desvenlafaxine%20Succinate%20Sustained%20Release%20In%20Adults%20With%20Major%20Depressive%20Disorder</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2009</study_first_submitted>
  <study_first_submitted_qc>March 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2009</study_first_posted>
  <results_first_submitted>March 8, 2011</results_first_submitted>
  <results_first_submitted_qc>April 7, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 6, 2011</results_first_posted>
  <last_update_submitted>April 7, 2011</last_update_submitted>
  <last_update_submitted_qc>April 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2011</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Wyeth</organization>
  </responsible_party>
  <keyword>Major Depressive Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Desvenlafaxine Succinate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 898 potential participants were screened for this study. 804 participants were enrolled and received single-blind placebo during the screening period prior to randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Matching placebo tablets daily until Day 56 (Week 8) or early termination (ET).</description>
        </group>
        <group group_id="P2">
          <title>DVS SR 10 mg</title>
          <description>Desvenlafaxine Succinate Sustained Release (DVS SR) 10 mg daily until Day 56 (Week 8) or ET.</description>
        </group>
        <group group_id="P3">
          <title>DVS SR 50 mg</title>
          <description>DVS SR 50 mg daily until Day 56 (Week 8) or ET.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="227"/>
                <participants group_id="P2" count="228"/>
                <participants group_id="P3" count="227"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="223"/>
                <participants group_id="P2" count="226"/>
                <participants group_id="P3" count="224"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="195"/>
                <participants group_id="P2" count="198"/>
                <participants group_id="P3" count="202"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="25"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant failed to return</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator request</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized not treated</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Matching placebo tablets daily until Day 56 (Week 8) or early termination (ET).</description>
        </group>
        <group group_id="B2">
          <title>DVS SR 10 mg</title>
          <description>Desvenlafaxine Succinate Sustained Release (DVS SR) 10 mg daily until Day 56 (Week 8) or ET.</description>
        </group>
        <group group_id="B3">
          <title>DVS SR 50 mg</title>
          <description>DVS SR 50 mg daily until Day 56 (Week 8) or ET.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="223"/>
            <count group_id="B2" value="226"/>
            <count group_id="B3" value="224"/>
            <count group_id="B4" value="673"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.75" spread="12.85"/>
                    <measurement group_id="B2" value="41.01" spread="13.75"/>
                    <measurement group_id="B3" value="42.47" spread="13.47"/>
                    <measurement group_id="B4" value="41.74" spread="13.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="139"/>
                    <measurement group_id="B2" value="135"/>
                    <measurement group_id="B3" value="135"/>
                    <measurement group_id="B4" value="409"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="89"/>
                    <measurement group_id="B4" value="264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hamilton Psychiatric Scale for Depression-17 item HAM-D17) total score</title>
          <description>HAM-D17 : a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Items are scored on either a 3 point (0 to 2) or a 5 point scale (0 to 4), with 0=none/absent and 4=most severe, for a maximum total score of 50.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.23" spread="2.63"/>
                    <measurement group_id="B2" value="22.83" spread="2.26"/>
                    <measurement group_id="B3" value="23.12" spread="2.62"/>
                    <measurement group_id="B4" value="23.06" spread="2.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Clinical Global Impressions Scale-Severity of Illness (CGI-S) Score</title>
          <description>CGI-S: 7-point clinician rated scale to assess severity of participant's current illness state; range: 1 (normal - not ill at all) to 7 (among the most extremely ill patients). Higher score = more affected.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.14" spread="0.35"/>
                    <measurement group_id="B2" value="4.14" spread="0.34"/>
                    <measurement group_id="B3" value="4.16" spread="0.39"/>
                    <measurement group_id="B4" value="4.14" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Montgomery-Asberg Depression Rating Scale (MADRS) total score</title>
          <description>MADRS measures the overall severity of depressive symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.33" spread="4.71"/>
                    <measurement group_id="B2" value="27.59" spread="4.49"/>
                    <measurement group_id="B3" value="28.44" spread="4.83"/>
                    <measurement group_id="B4" value="28.12" spread="4.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HAM-D6 total score</title>
          <description>HAM-D6: a standardized, clinician-administered rating scale that assesses 6 items associated with major depression and is a subset of the HAM-D17. HAM-D6 score ranges from 0-22. The scale uses HAM-D17 items: 1, 2, 7, 8, 10 and 13. Item 13 is scored 0-2 and all others are scored 0-4.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.72" spread="1.51"/>
                    <measurement group_id="B2" value="12.77" spread="1.41"/>
                    <measurement group_id="B3" value="12.63" spread="1.49"/>
                    <measurement group_id="B4" value="12.71" spread="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sheehan Disability Scale (SDS) Total Score</title>
          <description>SDS: a self-administered tool that measures functional impairment in 3 domains: Work/School, Social Life, and Family Life/Home Responsibilities.Participant rates extent to which each of these domains are impaired by his/her symptoms using 10 point visual analog scale:(0=not at all impaired,10=extremely impaired) for total maximum score of 30.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.88" spread="8.25"/>
                    <measurement group_id="B2" value="16.42" spread="8.37"/>
                    <measurement group_id="B3" value="17.06" spread="7.73"/>
                    <measurement group_id="B4" value="16.78" spread="8.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>World Health Organization 5-Item Well-Being Index (WHO-5)</title>
          <description>WHO-5 evaluates positive psychological well-being. WHO-5 consists of 5 questions and each is rated on a 6-point scale. The total score ranges from 0 to 25 ( 0= worst possible quality of life; 25=best possible quality of life).</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.39" spread="4.80"/>
                    <measurement group_id="B2" value="7.47" spread="4.86"/>
                    <measurement group_id="B3" value="7.06" spread="4.26"/>
                    <measurement group_id="B4" value="7.31" spread="4.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Participants with Sexual dysfunction</title>
          <description>Arizona Sexual Experiences Scale (ASEX) includes 5 questions that evaluate sexual function exclusively during week prior to completion in the following areas: libido, excitability and ability to reach orgasm. Sexual dysfunction=ASEX total score of 19 or greater, or a score of 5 or greater on any item, or a score of 4 or greater on any 3 items.</description>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.8"/>
                    <measurement group_id="B2" value="61.3"/>
                    <measurement group_id="B3" value="65.8"/>
                    <measurement group_id="B4" value="185.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Participants with Columbia Suicide-Severity Rating Scale (C-SSRS) total score</title>
          <description>C-SSRS was mapped into Columbia Classification Algorithm of Suicide Assessment (C-CASA)(1-4) to prospectively assess whether participants experienced: completed suicide(1),suicide attempt(2),preparatory acts toward imminent suicidal behavior(3),suicidal ideation,any suicidal behavior and ideation(4).Participants with “yes” response were reported.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Completed Suicide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicide Attempt</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Preparatory acts toward imminent suicidal behavior</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicidal ideation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in HAM-D17 Total Score at Final On-therapy (FOT) Evaluation (Week 8 or ET)</title>
        <description>HAM-D17: a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Items are scored on either a 3 point (0 to 2) or a 5 point scale (0 to 4), with 0=none/absent and 4=most severe, for a maximum total score of 50.</description>
        <time_frame>Baseline and Week 8 (or ET)</time_frame>
        <population>Intent-To-Treat (ITT) Population:all randomly assigned participants with baseline primary efficacy evaluation, had taken at least 1 dose of double-blind drug and 1 primary efficacy evaluation after first dose of double-blind drug. If participant had missing value at any visit, last observation carried forward (LOCF) method of imputation was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo tablets daily until Day 56 (Week 8) or early termination (ET).</description>
          </group>
          <group group_id="O2">
            <title>DVS SR 10 mg</title>
            <description>Desvenlafaxine Succinate Sustained Release (DVS SR) 10 mg daily until Day 56 (Week 8) or ET.</description>
          </group>
          <group group_id="O3">
            <title>DVS SR 50 mg</title>
            <description>DVS SR 50 mg daily until Day 56 (Week 8) or ET.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HAM-D17 Total Score at Final On-therapy (FOT) Evaluation (Week 8 or ET)</title>
          <description>HAM-D17: a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Items are scored on either a 3 point (0 to 2) or a 5 point scale (0 to 4), with 0=none/absent and 4=most severe, for a maximum total score of 50.</description>
          <population>Intent-To-Treat (ITT) Population:all randomly assigned participants with baseline primary efficacy evaluation, had taken at least 1 dose of double-blind drug and 1 primary efficacy evaluation after first dose of double-blind drug. If participant had missing value at any visit, last observation carried forward (LOCF) method of imputation was used.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.42" spread="0.45"/>
                    <measurement group_id="O2" value="-9.28" spread="0.45"/>
                    <measurement group_id="O3" value="-8.92" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>An analysis of covariance (ANCOVA) model with treatment and as a factor and the baseline HAM-D17 total score as a covariate was used to compare DVS SR 10 mg to placebo. The comparison was performed at the 0.05 level overall.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.175</p_value>
            <p_value_desc>A Hochberg step-up procedure was used to control for the multiplicity associated with multiple active dose arms.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.38</ci_lower_limit>
            <ci_upper_limit>2.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>An analysis of covariance (ANCOVA) model with treatment and as a factor and the baseline HAM-D17 total score as a covariate was used to compare DVS SR 10 mg to placebo. The comparison was performed at the 0.05 level overall.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.421</p_value>
            <p_value_desc>A Hochberg step-up procedure was used to control for the multiplicity associated with multiple active dose arms.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.73</ci_lower_limit>
            <ci_upper_limit>1.75</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Categorical Scores on CGI–Improvement (CGI-I) at FOT Evaluation (Week 8 or ET)</title>
        <description>CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected.</description>
        <time_frame>Week 8 (or ET)</time_frame>
        <population>ITT Population included all randomly assigned participants who had baseline primary efficacy evaluation, had taken at least 1 dose of double-blind study drug, and had at least 1 primary efficacy evaluation after first dose of double-blind study drug. If participant had a missing value at any visit, LOCF method of imputation was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo tablets daily until Day 56 (Week 8) or early termination (ET).</description>
          </group>
          <group group_id="O2">
            <title>DVS SR 10 mg</title>
            <description>Desvenlafaxine Succinate Sustained Release (DVS SR) 10 mg daily until Day 56 (Week 8) or ET.</description>
          </group>
          <group group_id="O3">
            <title>DVS SR 50 mg</title>
            <description>DVS SR 50 mg daily until Day 56 (Week 8) or ET.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Categorical Scores on CGI–Improvement (CGI-I) at FOT Evaluation (Week 8 or ET)</title>
          <description>CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected.</description>
          <population>ITT Population included all randomly assigned participants who had baseline primary efficacy evaluation, had taken at least 1 dose of double-blind study drug, and had at least 1 primary efficacy evaluation after first dose of double-blind study drug. If participant had a missing value at any visit, LOCF method of imputation was used.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1=Very much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2=Much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="75"/>
                    <measurement group_id="O3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3=Minimally improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4=No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5=Minimally worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6=Much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7=Very much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Each DVS SR dose was separately compared to placebo. To control the study-wise type I error rate across the primary and the key secondary endpoints, as well as across the 2 active dose arms, testing of the key secondary hypothesis occurred only when both active doses were superior to placebo on the primary endpoint.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.076</p_value>
            <p_value_desc>In this case, multiplicity arising from testing key secondary hypotheses in both doses was controlled by a Hochberg step-up procedure. p-Value obtained for the alternative hypothesis of `Row mean scores differences'.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Each DVS SR dose was separately compared to placebo. To control the study-wise type I error rate across the primary and the key secondary endpoints, as well as across the 2 active dose arms, testing of the key secondary hypothesis occurred only when both active doses were superior to placebo on the primary endpoint.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.204</p_value>
            <p_value_desc>In this case, multiplicity arising from testing key secondary hypotheses in both doses was controlled by a Hochberg step-up procedure. p-Value obtained for the alternative hypothesis of `Row mean scores differences'.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean CGI-S Score at FOT Evaluation (Week 8 or ET)</title>
        <description>CGI-S: 7-point clinician rated scale to assess severity of participant's current illness state; range: 1 (normal - not ill at all) to 7 (among the most extremely ill patients). Higher score = more affected.</description>
        <time_frame>Baseline and Week 8 (or ET )</time_frame>
        <population>ITT Population included all randomly assigned participants who had baseline primary efficacy evaluation, had taken at least 1 dose of double-blind study drug, and had at least 1 primary efficacy evaluation after first dose of double-blind study drug. If participant had a missing value at any visit, LOCF method of imputation was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo tablets daily until Day 56 (Week 8) or early termination (ET).</description>
          </group>
          <group group_id="O2">
            <title>DVS SR 10 mg</title>
            <description>Desvenlafaxine Succinate Sustained Release (DVS SR) 10 mg daily until Day 56 (Week 8) or ET.</description>
          </group>
          <group group_id="O3">
            <title>DVS SR 50 mg</title>
            <description>DVS SR 50 mg daily until Day 56 (Week 8) or ET.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean CGI-S Score at FOT Evaluation (Week 8 or ET)</title>
          <description>CGI-S: 7-point clinician rated scale to assess severity of participant's current illness state; range: 1 (normal - not ill at all) to 7 (among the most extremely ill patients). Higher score = more affected.</description>
          <population>ITT Population included all randomly assigned participants who had baseline primary efficacy evaluation, had taken at least 1 dose of double-blind study drug, and had at least 1 primary efficacy evaluation after first dose of double-blind study drug. If participant had a missing value at any visit, LOCF method of imputation was used.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.08" spread="0.07"/>
                    <measurement group_id="O2" value="-1.23" spread="0.07"/>
                    <measurement group_id="O3" value="-1.11" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis was conducted using ANCOVA on the change from baseline with treatment as a factor and corresponding baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.130</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.04</ci_lower_limit>
            <ci_upper_limit>0.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis was conducted using ANCOVA on the change from baseline with treatment as a factor and corresponding baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.757</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.16</ci_lower_limit>
            <ci_upper_limit>0.23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in MADRS Total Score at FOT Evaluation (Week 8 or ET)</title>
        <description>MADRS measures the overall severity of depressive symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).</description>
        <time_frame>Baseline and Week 8 (or ET)</time_frame>
        <population>ITT Population included all randomly assigned participants who had baseline primary efficacy evaluation, had taken at least 1 dose of double-blind study drug, and had at least 1 primary efficacy evaluation after first dose of double-blind study drug. If participant had a missing value at any visit, LOCF method of imputation was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo tablets daily until Day 56 (Week 8) or early termination (ET).</description>
          </group>
          <group group_id="O2">
            <title>DVS SR 10 mg</title>
            <description>Desvenlafaxine Succinate Sustained Release (DVS SR) 10 mg daily until Day 56 (Week 8) or ET.</description>
          </group>
          <group group_id="O3">
            <title>DVS SR 50 mg</title>
            <description>DVS SR 50 mg daily until Day 56 (Week 8) or ET.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in MADRS Total Score at FOT Evaluation (Week 8 or ET)</title>
          <description>MADRS measures the overall severity of depressive symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).</description>
          <population>ITT Population included all randomly assigned participants who had baseline primary efficacy evaluation, had taken at least 1 dose of double-blind study drug, and had at least 1 primary efficacy evaluation after first dose of double-blind study drug. If participant had a missing value at any visit, LOCF method of imputation was used.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="222"/>
                <count group_id="O2" value="224"/>
                <count group_id="O3" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.87" spread="0.63"/>
                    <measurement group_id="O2" value="-11.28" spread="0.63"/>
                    <measurement group_id="O3" value="-10.76" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis was conducted using ANCOVA on the change from baseline with treatment as a factor and corresponding baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.114</p_value>
            <method>ANCOVA</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>1.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.34</ci_lower_limit>
            <ci_upper_limit>3.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis was conducted using ANCOVA on the change from baseline with treatment as a factor and corresponding baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.316</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.85</ci_lower_limit>
            <ci_upper_limit>2.64</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HAM-D6 Total Score at FOT Evaluation (Week 8 or ET)</title>
        <description>HAM-D6: a standardized, clinician-administered rating scale that assesses 6 items characteristically associated with major depression and is a subset of HAM-D17. HAM-D6 score ranges from 0-22. 0=none/absent and 22=most severe.The scale uses HAM-D17 items: 1, 2, 7, 8, 10 and 13. Item 13 is scored 0-2 and all others are scored 0-4.</description>
        <time_frame>Baseline and Week 8 (or ET )</time_frame>
        <population>ITT Population included all randomly assigned participants who had baseline primary efficacy evaluation, had taken at least 1 dose of double-blind study drug, and had at least 1 primary efficacy evaluation after first dose of double-blind study drug. If participant had a missing value at any visit, LOCF method of imputation was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo tablets daily until Day 56 (Week 8) or early termination (ET).</description>
          </group>
          <group group_id="O2">
            <title>DVS SR 10 mg</title>
            <description>Desvenlafaxine Succinate Sustained Release (DVS SR) 10 mg daily until Day 56 (Week 8) or ET.</description>
          </group>
          <group group_id="O3">
            <title>DVS SR 50 mg</title>
            <description>DVS SR 50 mg daily until Day 56 (Week 8) or ET.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HAM-D6 Total Score at FOT Evaluation (Week 8 or ET)</title>
          <description>HAM-D6: a standardized, clinician-administered rating scale that assesses 6 items characteristically associated with major depression and is a subset of HAM-D17. HAM-D6 score ranges from 0-22. 0=none/absent and 22=most severe.The scale uses HAM-D17 items: 1, 2, 7, 8, 10 and 13. Item 13 is scored 0-2 and all others are scored 0-4.</description>
          <population>ITT Population included all randomly assigned participants who had baseline primary efficacy evaluation, had taken at least 1 dose of double-blind study drug, and had at least 1 primary efficacy evaluation after first dose of double-blind study drug. If participant had a missing value at any visit, LOCF method of imputation was used.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.75" spread="0.27"/>
                    <measurement group_id="O2" value="-5.49" spread="0.27"/>
                    <measurement group_id="O3" value="-5.19" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis was conducted using ANCOVA on the change from baseline with treatment as a factor and corresponding baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.054</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.01</ci_lower_limit>
            <ci_upper_limit>1.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis was conducted using ANCOVA on the change from baseline with treatment as a factor and corresponding baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.253</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.32</ci_lower_limit>
            <ci_upper_limit>1.20</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Response on the HAM-D17 at FOT Evaluation (Week 8 or ET)</title>
        <description>A HAM-D17 responder was defined as a participant with a 50% or greater decrease from baseline in HAM-D17 score. HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Individual items are scored on either a 3 point (0 to 2) or a 5 point scale (0 to 4), with 0=none/absent and 4=most severe, for a maximum total score of 50.</description>
        <time_frame>Week 8 (or ET)</time_frame>
        <population>ITT Population included all randomly assigned participants who had baseline primary efficacy evaluation, had taken at least 1 dose of double-blind study drug, and had at least 1 primary efficacy evaluation after first dose of double-blind study drug. If participant had a missing value at any visit, LOCF method of imputation was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo tablets daily until Day 56 (Week 8) or early termination (ET).</description>
          </group>
          <group group_id="O2">
            <title>DVS SR 10 mg</title>
            <description>Desvenlafaxine Succinate Sustained Release (DVS SR) 10 mg daily until Day 56 (Week 8) or ET.</description>
          </group>
          <group group_id="O3">
            <title>DVS SR 50 mg</title>
            <description>DVS SR 50 mg daily until Day 56 (Week 8) or ET.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Response on the HAM-D17 at FOT Evaluation (Week 8 or ET)</title>
          <description>A HAM-D17 responder was defined as a participant with a 50% or greater decrease from baseline in HAM-D17 score. HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Individual items are scored on either a 3 point (0 to 2) or a 5 point scale (0 to 4), with 0=none/absent and 4=most severe, for a maximum total score of 50.</description>
          <population>ITT Population included all randomly assigned participants who had baseline primary efficacy evaluation, had taken at least 1 dose of double-blind study drug, and had at least 1 primary efficacy evaluation after first dose of double-blind study drug. If participant had a missing value at any visit, LOCF method of imputation was used.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis was conducted using a logistic regression model with treatment as a factor and baseline HAM-D17 score as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2415</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.254</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis was conducted using a logistic regression model with treatment as a factor and baseline HAM-D17 score as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6169</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.102</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.61</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants in Remission Based on the HAM-D17 at FOT Evaluation (Week 8 or ET)</title>
        <description>Remission was defined as a HAM-D17 score of less than or equal to 7. HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Individual items are scored on either a 3 point (0 to 2) or a 5 point scale (0 to 4), with 0=none/absent and 4=most severe, for a maximum total score of 50.</description>
        <time_frame>Week 8 (or ET)</time_frame>
        <population>ITT Population included all randomly assigned participants who had baseline primary efficacy evaluation, had taken at least 1 dose of double-blind study drug, and had at least 1 primary efficacy evaluation after first dose of double-blind study drug. If participant had a missing value at any visit, LOCF method of imputation was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo tablets daily until Day 56 (Week 8) or early termination (ET).</description>
          </group>
          <group group_id="O2">
            <title>DVS SR 10 mg</title>
            <description>Desvenlafaxine Succinate Sustained Release (DVS SR) 10 mg daily until Day 56 (Week 8) or ET.</description>
          </group>
          <group group_id="O3">
            <title>DVS SR 50 mg</title>
            <description>DVS SR 50 mg daily until Day 56 (Week 8) or ET.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants in Remission Based on the HAM-D17 at FOT Evaluation (Week 8 or ET)</title>
          <description>Remission was defined as a HAM-D17 score of less than or equal to 7. HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Individual items are scored on either a 3 point (0 to 2) or a 5 point scale (0 to 4), with 0=none/absent and 4=most severe, for a maximum total score of 50.</description>
          <population>ITT Population included all randomly assigned participants who had baseline primary efficacy evaluation, had taken at least 1 dose of double-blind study drug, and had at least 1 primary efficacy evaluation after first dose of double-blind study drug. If participant had a missing value at any visit, LOCF method of imputation was used.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis was conducted using a logistic regression model with treatment as a factor and baseline HAM-D17 score as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3667</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.236</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>1.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis was conducted using a logistic regression model with treatment as a factor and baseline HAM-D17 score as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6509</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.894</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>1.45</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Response on the MADRS Score at FOT Evaluation (Week 8 or ET)</title>
        <description>A MADRS responder was defined as a participant with a 50% or greater decrease from baseline in MADRS score. It measures the overall severity of depressive symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).</description>
        <time_frame>Week 8 (or ET)</time_frame>
        <population>ITT Population included all randomly assigned participants who had baseline primary efficacy evaluation, had taken at least 1 dose of double-blind study drug, and had at least 1 primary efficacy evaluation after first dose of double-blind study drug. If participant had a missing value at any visit, LOCF method of imputation was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo tablets daily until Day 56 (Week 8) or early termination (ET).</description>
          </group>
          <group group_id="O2">
            <title>DVS SR 10 mg</title>
            <description>Desvenlafaxine Succinate Sustained Release (DVS SR) 10 mg daily until Day 56 (Week 8) or ET.</description>
          </group>
          <group group_id="O3">
            <title>DVS SR 50 mg</title>
            <description>DVS SR 50 mg daily until Day 56 (Week 8) or ET.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Response on the MADRS Score at FOT Evaluation (Week 8 or ET)</title>
          <description>A MADRS responder was defined as a participant with a 50% or greater decrease from baseline in MADRS score. It measures the overall severity of depressive symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).</description>
          <population>ITT Population included all randomly assigned participants who had baseline primary efficacy evaluation, had taken at least 1 dose of double-blind study drug, and had at least 1 primary efficacy evaluation after first dose of double-blind study drug. If participant had a missing value at any visit, LOCF method of imputation was used.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="222"/>
                <count group_id="O2" value="224"/>
                <count group_id="O3" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="95"/>
                    <measurement group_id="O3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis would be conducted with a logistic regression model with treatment as a factor and baseline MADRS score as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3893</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.182</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis would be conducted with a logistic regression model with treatment as a factor and baseline MADRS score as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5510</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.123</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>1.65</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Response on the CGI-I Score at FOT Evaluation (Week 8 or ET)</title>
        <description>CGI-I responder was defined as a participant with a score of 1 (very much improved) or 2 (much improved) on the CGI-I. CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected.</description>
        <time_frame>Week 8 (or ET)</time_frame>
        <population>ITT Population included all randomly assigned participants who had baseline primary efficacy evaluation, had taken at least 1 dose of double-blind study drug, and had at least 1 primary efficacy evaluation after first dose of double-blind study drug. If participant had a missing value at any visit, LOCF method of imputation was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo tablets daily until Day 56 (Week 8) or early termination (ET).</description>
          </group>
          <group group_id="O2">
            <title>DVS SR 10 mg</title>
            <description>Desvenlafaxine Succinate Sustained Release (DVS SR) 10 mg daily until Day 56 (Week 8) or ET.</description>
          </group>
          <group group_id="O3">
            <title>DVS SR 50 mg</title>
            <description>DVS SR 50 mg daily until Day 56 (Week 8) or ET.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Response on the CGI-I Score at FOT Evaluation (Week 8 or ET)</title>
          <description>CGI-I responder was defined as a participant with a score of 1 (very much improved) or 2 (much improved) on the CGI-I. CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected.</description>
          <population>ITT Population included all randomly assigned participants who had baseline primary efficacy evaluation, had taken at least 1 dose of double-blind study drug, and had at least 1 primary efficacy evaluation after first dose of double-blind study drug. If participant had a missing value at any visit, LOCF method of imputation was used.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="125"/>
                    <measurement group_id="O3" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis would be conducted with a logistic regression model with treatment as a factor.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0536</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.442</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.99</ci_lower_limit>
            <ci_upper_limit>2.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis would be conducted with a logistic regression model with treatment as a factor.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6679</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.085</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.57</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Population Pharmacokinetics for Desvenlafaxine Plasma Concentrations</title>
        <description>Relationship of demographic variables (age, gender, food, race, creatinine, aspartate aminotransaminase, alanine transaminase, bilirubin and concomitant medications) were examined by fitting measured DVS plasma concentrations to a 1 compartment model with first order absorption. Demographic variables were examined for clearance (CL/F), volume of distribution (V/F), Steady Area under Curve (AUC) using nonlinear mixed effects modeling. Final parameter estimates for demographic factors effecting CL/F, V/F and AUC were determined.</description>
        <time_frame>Week 2, 4 and 8 (or ET)</time_frame>
        <population>PK population; data was insufficient examine the effect of demographic variables on the PK of desvenlafaxine. Parameter values were calculated for variables altering CL/F, AUC and V/F. Population parameters from nonlinear mixed effects modeling were not summarized as descriptive statistics.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo tablets daily until Day 56 (Week 8) or early termination (ET).</description>
          </group>
          <group group_id="O2">
            <title>DVS SR 10 mg</title>
            <description>Desvenlafaxine Succinate Sustained Release (DVS SR) 10 mg daily until Day 56 (Week 8) or ET.</description>
          </group>
          <group group_id="O3">
            <title>DVS SR 50 mg</title>
            <description>DVS SR 50 mg daily until Day 56 (Week 8) or ET.</description>
          </group>
        </group_list>
        <measure>
          <title>Population Pharmacokinetics for Desvenlafaxine Plasma Concentrations</title>
          <description>Relationship of demographic variables (age, gender, food, race, creatinine, aspartate aminotransaminase, alanine transaminase, bilirubin and concomitant medications) were examined by fitting measured DVS plasma concentrations to a 1 compartment model with first order absorption. Demographic variables were examined for clearance (CL/F), volume of distribution (V/F), Steady Area under Curve (AUC) using nonlinear mixed effects modeling. Final parameter estimates for demographic factors effecting CL/F, V/F and AUC were determined.</description>
          <population>PK population; data was insufficient examine the effect of demographic variables on the PK of desvenlafaxine. Parameter values were calculated for variables altering CL/F, AUC and V/F. Population parameters from nonlinear mixed effects modeling were not summarized as descriptive statistics.</population>
          <units>nanogram(ng)/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in SDS at FOT Evaluation (Week 8 or ET)</title>
        <description>SDS: a self-administered tools that measures functional impairment in 3 domains: Work/School, Social Life, and Family Life/Home Responsibilities. The participant rates the extent to which each of these domains is impaired by his/her symptoms using a 10 point visual analog scale: (0=not at all impaired, 10=extremely impaired) for a total maximum score of 30.</description>
        <time_frame>Baseline and Week 8 (or ET)</time_frame>
        <population>ITT Population included all randomly assigned participants who had baseline primary efficacy evaluation,had taken at least 1 dose of double-blind study drug,had at least 1 primary efficacy evaluation after first dose of double-blind drug.'n' is participants who received drug and were evaluated for measure at timepoint for each group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo tablets daily until Day 56 (Week 8) or early termination (ET).</description>
          </group>
          <group group_id="O2">
            <title>DVS SR 10 mg</title>
            <description>Desvenlafaxine Succinate Sustained Release (DVS SR) 10 mg daily until Day 56 (Week 8) or ET.</description>
          </group>
          <group group_id="O3">
            <title>DVS SR 50 mg</title>
            <description>DVS SR 50 mg daily until Day 56 (Week 8) or ET.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SDS at FOT Evaluation (Week 8 or ET)</title>
          <description>SDS: a self-administered tools that measures functional impairment in 3 domains: Work/School, Social Life, and Family Life/Home Responsibilities. The participant rates the extent to which each of these domains is impaired by his/her symptoms using a 10 point visual analog scale: (0=not at all impaired, 10=extremely impaired) for a total maximum score of 30.</description>
          <population>ITT Population included all randomly assigned participants who had baseline primary efficacy evaluation,had taken at least 1 dose of double-blind study drug,had at least 1 primary efficacy evaluation after first dose of double-blind drug.'n' is participants who received drug and were evaluated for measure at timepoint for each group respectively.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Score (n=220,223,219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.63" spread="0.48"/>
                    <measurement group_id="O2" value="-4.09" spread="0.48"/>
                    <measurement group_id="O3" value="-3.78" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Work/Studies Component(n=220,223,219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.61" spread="0.17"/>
                    <measurement group_id="O2" value="-1.10" spread="0.17"/>
                    <measurement group_id="O3" value="-1.14" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Life and Leisure Activities(n=222,224,221)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.08" spread="0.18"/>
                    <measurement group_id="O2" value="-1.58" spread="0.17"/>
                    <measurement group_id="O3" value="-1.36" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Family Life/Home Responsibilities (n=222,224,221)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.98" spread="0.17"/>
                    <measurement group_id="O2" value="-1.43" spread="0.17"/>
                    <measurement group_id="O3" value="-1.20" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis was conducted using ANCOVA on the change from baseline with treatment as a factor and corresponding baseline value as a covariate for &quot;total score&quot;.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.033</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.12</ci_lower_limit>
            <ci_upper_limit>2.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis was conducted using ANCOVA on the change from baseline with treatment as a factor and corresponding baseline value as a covariate for &quot;total score&quot;.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.096</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.20</ci_lower_limit>
            <ci_upper_limit>2.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis was conducted using ANCOVA on the change from baseline with treatment as a factor and corresponding baseline value as a covariate for &quot;work/studies component score&quot;.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.043</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.02</ci_lower_limit>
            <ci_upper_limit>0.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis was conducted using ANCOVA on the change from baseline with treatment as a factor and corresponding baseline value as a covariate for &quot;work/studies component score&quot;.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.027</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.06</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis was conducted using ANCOVA on the change from baseline with treatment as a factor and corresponding baseline value as a covariate for &quot;social life and leisure activities component score&quot;.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.045</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.01</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis was conducted using ANCOVA on the change from baseline with treatment as a factor and corresponding baseline value as a covariate for &quot;social life and leisure activities component score&quot;.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.277</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.22</ci_lower_limit>
            <ci_upper_limit>0.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis was conducted using ANCOVA on the change from baseline with treatment as a factor and corresponding baseline value as a covariate for &quot;family life/home responsibilities component score&quot;.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.056</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.01</ci_lower_limit>
            <ci_upper_limit>0.91</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis was conducted using ANCOVA on the change from baseline with treatment as a factor and corresponding baseline value as a covariate for &quot;family life/home responsibilities component score&quot;.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.355</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.24</ci_lower_limit>
            <ci_upper_limit>0.68</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in WHO-5 Total Score at FOT Evaluation (Week 8 or ET)</title>
        <description>WHO-5 evaluates positive psychological well-being. WHO-5 consists of 5 questions and each is rated on a 6-point scale. The total score ranges from 0 to 25 (0= worst possible quality of life; 25=best possible quality of life).</description>
        <time_frame>Baseline and Week 8 (or ET)</time_frame>
        <population>ITT Population included all randomly assigned participants who had baseline primary efficacy evaluation, had taken at least 1 dose of double-blind study drug, and had at least 1 primary efficacy evaluation after first dose of double-blind study drug. If participant had a missing value at any visit, LOCF method of imputation was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo tablets daily until Day 56 (Week 8) or early termination (ET).</description>
          </group>
          <group group_id="O2">
            <title>DVS SR 10 mg</title>
            <description>Desvenlafaxine Succinate Sustained Release (DVS SR) 10 mg daily until Day 56 (Week 8) or ET.</description>
          </group>
          <group group_id="O3">
            <title>DVS SR 50 mg</title>
            <description>DVS SR 50 mg daily until Day 56 (Week 8) or ET.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in WHO-5 Total Score at FOT Evaluation (Week 8 or ET)</title>
          <description>WHO-5 evaluates positive psychological well-being. WHO-5 consists of 5 questions and each is rated on a 6-point scale. The total score ranges from 0 to 25 (0= worst possible quality of life; 25=best possible quality of life).</description>
          <population>ITT Population included all randomly assigned participants who had baseline primary efficacy evaluation, had taken at least 1 dose of double-blind study drug, and had at least 1 primary efficacy evaluation after first dose of double-blind study drug. If participant had a missing value at any visit, LOCF method of imputation was used.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="222"/>
                <count group_id="O2" value="224"/>
                <count group_id="O3" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.96" spread="0.36"/>
                    <measurement group_id="O2" value="4.51" spread="0.35"/>
                    <measurement group_id="O3" value="3.73" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis was conducted using ANCOVA on the change from baseline with treatment as a factor and corresponding baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.53</ci_lower_limit>
            <ci_upper_limit>-0.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis was conducted using ANCOVA on the change from baseline with treatment as a factor and corresponding baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.129</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.75</ci_lower_limit>
            <ci_upper_limit>0.22</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants With Sexual Dysfunction at FOT Evaluation (Week 8 or ET)</title>
        <description>ASEX scale includes 5 questions that evaluate sexual function exclusively during the week prior to completion in the following areas: libido, excitability and ability to reach orgasm. Sexual dysfunction=an ASEX total score of 19 or greater, or a score of 5 or greater on any item, or a score of 4 or greater on any 3 items. Participants who have had no sexual activity during the prior week were instructed to not complete questions 3 through 5.</description>
        <time_frame>Week 8 (or ET)</time_frame>
        <population>The safety population included all participants randomly assigned to treatment who had taken at least 1 dose of double-blind study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo tablets daily until Day 56 (Week 8) or early termination (ET).</description>
          </group>
          <group group_id="O2">
            <title>DVS SR 10 mg</title>
            <description>Desvenlafaxine Succinate Sustained Release (DVS SR) 10 mg daily until Day 56 (Week 8) or ET.</description>
          </group>
          <group group_id="O3">
            <title>DVS SR 50 mg</title>
            <description>DVS SR 50 mg daily until Day 56 (Week 8) or ET.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Sexual Dysfunction at FOT Evaluation (Week 8 or ET)</title>
          <description>ASEX scale includes 5 questions that evaluate sexual function exclusively during the week prior to completion in the following areas: libido, excitability and ability to reach orgasm. Sexual dysfunction=an ASEX total score of 19 or greater, or a score of 5 or greater on any item, or a score of 4 or greater on any 3 items. Participants who have had no sexual activity during the prior week were instructed to not complete questions 3 through 5.</description>
          <population>The safety population included all participants randomly assigned to treatment who had taken at least 1 dose of double-blind study drug.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="221"/>
                <count group_id="O2" value="222"/>
                <count group_id="O3" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.0"/>
                    <measurement group_id="O2" value="48.6"/>
                    <measurement group_id="O3" value="59.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis was conducted using a logistic regression model with treatment and gender as factors and baseline sexual dysfunction status as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3097</p_value>
            <method>Regression, Linear</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.800</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.52</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis was conducted using a logistic regression model with treatment and gender as factors and baseline sexual dysfunction status as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2794</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.272</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.97</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Categorical Scores on the C-SSRS at FOT Evaluation (Week 8 or ET)</title>
        <description>C-SSRS mapped into C-CASA(1-7) to assess whether participant:completed suicide(1),suicide attempt(2)(response of “Yes” on “Actual Attempt”),preparatory acts toward imminent suicidal behavior (3)(“Yes” on “Preparatory Acts or Behavior”),suicidal ideation (4)(“Yes” on “Wish to be dead”,“Non-Specific Active Suicidal Thoughts”,“Active Suicidal Ideation with methods without Intent to Act or Some Intent to Act,without Specific Plan or with Specific Plan and Intent),any suicidal behavior or ideation,self-injurious behaviour(7)(“Yes” on “Has subject engaged in Non-suicidal Self-Injurious Behavior”).</description>
        <time_frame>Week 8 (or ET)</time_frame>
        <population>The safety population included all participants randomly assigned to treatment who had taken at least 1 dose of double-blind study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo tablets daily until Day 56 (Week 8) or early termination (ET).</description>
          </group>
          <group group_id="O2">
            <title>DVS SR 10 mg</title>
            <description>Desvenlafaxine Succinate Sustained Release (DVS SR) 10 mg daily until Day 56 (Week 8) or ET.</description>
          </group>
          <group group_id="O3">
            <title>DVS SR 50 mg</title>
            <description>DVS SR 50 mg daily until Day 56 (Week 8) or ET.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Categorical Scores on the C-SSRS at FOT Evaluation (Week 8 or ET)</title>
          <description>C-SSRS mapped into C-CASA(1-7) to assess whether participant:completed suicide(1),suicide attempt(2)(response of “Yes” on “Actual Attempt”),preparatory acts toward imminent suicidal behavior (3)(“Yes” on “Preparatory Acts or Behavior”),suicidal ideation (4)(“Yes” on “Wish to be dead”,“Non-Specific Active Suicidal Thoughts”,“Active Suicidal Ideation with methods without Intent to Act or Some Intent to Act,without Specific Plan or with Specific Plan and Intent),any suicidal behavior or ideation,self-injurious behaviour(7)(“Yes” on “Has subject engaged in Non-suicidal Self-Injurious Behavior”).</description>
          <population>The safety population included all participants randomly assigned to treatment who had taken at least 1 dose of double-blind study drug.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Completed suicide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicide attempt</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Preparatory acts toward imminent suicidal behavior</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicidal ideation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any suicidal behavior and/or ideation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Self-injurious behavior, no suicidal intent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Discontinuation-Emergent Signs and Symptoms (DESS)</title>
        <description>DESS: a clinician-administered 43-item assessment that evaluates discontinuation-emergent symptoms resulting from the withdrawal from test article. The DESS total score is the sum of the number of new symptoms and old (but worse) symptoms that appeared during tapering of the test article. A higher score indicates more symptoms.</description>
        <time_frame>Week 8 to 10 (or ET)</time_frame>
        <population>Analysis included completers for exposure (those whose exposure duration was at least 53 days) among safety population. 'n' is participants who received drug and were evaluated for measure at timepoint for each group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo tablets daily until Day 56 (Week 8) or early termination (ET).</description>
          </group>
          <group group_id="O2">
            <title>DVS SR 10 mg</title>
            <description>Desvenlafaxine Succinate Sustained Release (DVS SR) 10 mg daily until Day 56 (Week 8) or ET.</description>
          </group>
          <group group_id="O3">
            <title>DVS SR 50 mg</title>
            <description>DVS SR 50 mg daily until Day 56 (Week 8) or ET.</description>
          </group>
        </group_list>
        <measure>
          <title>Discontinuation-Emergent Signs and Symptoms (DESS)</title>
          <description>DESS: a clinician-administered 43-item assessment that evaluates discontinuation-emergent symptoms resulting from the withdrawal from test article. The DESS total score is the sum of the number of new symptoms and old (but worse) symptoms that appeared during tapering of the test article. A higher score indicates more symptoms.</description>
          <population>Analysis included completers for exposure (those whose exposure duration was at least 53 days) among safety population. 'n' is participants who received drug and were evaluated for measure at timepoint for each group respectively.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 8 (or ET) (n=190,194,191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.72" spread="1.81"/>
                    <measurement group_id="O2" value="0.80" spread="1.78"/>
                    <measurement group_id="O3" value="0.83" spread="2.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9 ( or ET + 1 week) (n=178,185,186)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.26" spread="2.78"/>
                    <measurement group_id="O2" value="1.08" spread="2.31"/>
                    <measurement group_id="O3" value="1.98" spread="3.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10 (or ET + 2 weeks (n=170,182,182)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90" spread="2.30"/>
                    <measurement group_id="O2" value="0.91" spread="2.24"/>
                    <measurement group_id="O3" value="1.07" spread="2.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To address the multiplicity effect inherent in these comparisons, adjusted p-values based on the false discovery rate was used at Week 8.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.805</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To address the multiplicity effect inherent in these comparisons, adjusted p-values based on the false discovery rate was used at Week 9.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.805</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To address the multiplicity effect inherent in these comparisons, adjusted p-values based on the false discovery rate was used at Week 10.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.978</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>To address the multiplicity effect inherent in these comparisons, adjusted p-values based on the false discovery rate was used at Week 8.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.805</p_value>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>To address the multiplicity effect inherent in these comparisons, adjusted p-values based on the false discovery rate was used at Week 9.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.154</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>To address the multiplicity effect inherent in these comparisons, adjusted p-values based on the false discovery rate was used at Week 10.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.805</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Matching placebo tablets daily until Day 56 (Week 8) or early termination (ET).</description>
        </group>
        <group group_id="E2">
          <title>DVS SR 10 mg</title>
          <description>Desvenlafaxine Succinate Sustained Release (DVS SR) 10 mg daily until Day 56 (Week 8) or ET.</description>
        </group>
        <group group_id="E3">
          <title>DVS SR 50 mg</title>
          <description>DVS SR 50 mg daily until Day 56 (Week 8) or ET.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Scrotal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="166" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="168" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="170" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Polycythaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Cardiac hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Supraventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Hyperacusis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blepharospasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Excessive eye blinking</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Miosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Photopsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Chapped lips</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Eructation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Faeces discoloured</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Faeces pale</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Frequent bowel movements</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Pancreatic cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Salivary hypersecretion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Vomiting in pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Feeling abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Feeling jittery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Temperature intolerance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acarodermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Bronchitis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Gingival infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>H1N1 influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Infected bites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Infected cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Meningitis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Vaginitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Back injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Epicondylitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Blood calcium increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Blood human chorionic gonadotropin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Blood pressure decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Blood pressure diastolic decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Blood pressure diastolic increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Blood pressure orthostatic decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Blood pressure systolic decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Blood prolactin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Electrocardiogram T wave amplitude decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Electrocardiogram T wave inversion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Heart rate irregular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Platelet count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Protein urine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Tuberculin test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol intolerance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Food craving</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Glucose tolerance impaired</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Hypernatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Hyperphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Hyperproteinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Fibromyalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Joint stiffness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Muscle tightness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Muscle twitching</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Musculoskeletal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Myokymia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Plantar fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Sensation of heaviness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Abdominal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Melanocytic naevus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Akathisia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Drug withdrawal headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Exaggerated startle response</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Hypersomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Hypogeusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Poor quality sleep</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Restless legs syndrome</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Syncop</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal dreams</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Anger</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Anorgasmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Bradyphrenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Bruxism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Depersonalisation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Derealisation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Dissociation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Distractibility</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Elevated mood</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Impulse-control disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Initial insomnia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Libido decreased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Loss of libido</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Middle insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Mood altered</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Mood swings</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Nightmare</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Orgasm abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Orgasmic sensation decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Panic disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Self injurious behaviour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Tearfulness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Terminal insomnia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Chromaturia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Micturition urgency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Polyuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Urge incontinence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Urinary hesitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Urine odour abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast enlargement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Breast mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Breast tenderness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Ejaculation delayed</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Menstruation irregular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Oligomenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Prostatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Sexual dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Spontaneous penile erection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Vaginal odour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Choking</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Yawning</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Cold sweat</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia facial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Increased tendency to bruise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Ingrowing nail</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Keloid scar</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Orthostatic hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Systolic hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

